COMMUNIQUÉS West-GlobeNewswire

Quipt Home Medical Completes the Previously Announced Arrangement With Affiliates of Kingswood and Forager
16/03/2026
CINCINNATI, March 16, 2026 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ” or “ Quipt ”) (NASDAQ: QIPT; TSX: QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, is [...]
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
16/03/2026
- 12-patient cohort fully enrolled with an average time since transplant of approximately 8 months - 100% insulin independence achieved in 10 patients who are over 4 weeks post-transplant - No signs of graft rejection [...]
NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer
16/03/2026
FDA confirmed givastomig’s potential eligibility for an accelerated approval pathway NovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective response rate (ORR) as [...]
Doctomatic Appoints Tech Veteran Bill Josko as Head of Americas to Scale AI-Driven Remote Patient Monitoring
16/03/2026
BARCELONA, Spain, March 16, 2026 (GLOBE NEWSWIRE) -- Doctomatic, an AI-native platform for remote patient management, announces the appointment of Bill Josko as Head of Americas. Josko, a seasoned executive with more [...]
MediciNova to Participate at the 38th Annual ROTH Conference
16/03/2026
LA JOLLA, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics
16/03/2026
Financing led by The Venture Collective with participation from Merck Global Health Innovation Fund, Artis Ventures, First Spark Ventures, argenx, Droia Ventures and existing investors SANTA CRUZ, Calif., March 16, 2026 [...]
Avicanna Announces Sponsorship of University of Calgary THC Dose Finding Clinical Trial
16/03/2026
New randomized controlled trial to evaluate dose-dependent effects of oral THC on anxiety and stress using Avicanna’s proprietary capsules TORONTO, March 16, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “ [...]
Novo Nordisk A/S - share repurchase programme
16/03/2026
Bagsværd, Denmark, 16 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
16/03/2026
WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms [...]
Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26
16/03/2026
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, March 16, 2026 (GLOBE NEWSWIRE [...]
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
16/03/2026
On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollment in the OPERA-02 [...]
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
16/03/2026
JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free [...]
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
16/03/2026
MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
16/03/2026
Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella’s lead product candidate from the QTORIN™ platform, in development for serious, rare skin diseases and vascular malformations [...]
Sotera Health Appoints Kenneth D. Krause to the Board of Directors
16/03/2026
CLEVELAND, March 16, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company” or “Sotera Health”), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and [...]
CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
16/03/2026
- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - Grade 3 diarrhea [...]
Tilray Brands Enters Agreement to Acquire BrewDog’s Key U.S. Assets, Expanding Its U.S. Craft Beer Platform
16/03/2026
NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the [...]
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
16/03/2026
Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral GLP-1RAs and [...]
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
16/03/2026
- Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results - - Topline results of the global Phase 2 [...]

Pages